Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Statins--attaining goal values--with reference to recent studies].

H Toplak1, K Schallmoser, A DeCampo

  • 1Medizinischen Universitätsklinik Graz. hermann.toplak@kfunigraz.ac.at

Wiener Medizinische Wochenschrift (1946)
|July 17, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity.

European journal of endocrinology·2019
Same author

Prevalence of endocrine disorders in obese patients: systematic review and meta-analysis.

European journal of endocrinology·2019
Same author

International Forum on GMP-grade human platelet lysate for cell propagation: summary.

Vox sanguinis·2017
Same author

International Forum on GMP-grade human platelet lysate for cell propagation.

Vox sanguinis·2017
Same author

T-cell death, phosphatidylserine exposure and reduced proliferation rate to validate extracorporeal photochemotherapy.

Vox sanguinis·2014
Same author

[New AHA and ACC guidelines on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk : Statement of the D•A•CH Society for Prevention of Cardiovascular Diseases, the Austrian Atherosclerosis Society and the Working Group on Lipids and Atherosclerosis (AGLA) of the Swiss Society for Cardiology].

Der Internist·2014
Same journal

Necrotizing fasciitis of the thigh-a devastating sign of intestinal perforation.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Regenerative therapies in rehabilitation with interfaces with occupational medicine, geriatrics, and oncology: the example of extracorporeal shock wave therapy.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Cerebral toxoplasmosis in patients with peripheral B-cell lymphoma : A case series and a literature review.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Post-pandemic rebound of rotavirus and adenovirus in pediatric gastroenteritis: a 6-year antigen-based surveillance study from Turkey.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Neuroaxis involvement in Chikungunya virus infection: a retrospective case series.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

A complicated case of a spinal Scedosporium apiospermum infection with a favorable outcome-case report.

Wiener medizinische Wochenschrift (1946)·2026
See all related articles

Aggressive lipid lowering therapy, particularly with statins, is crucial for cardiovascular risk management in both primary and secondary prevention. Studies suggest aiming for the lowest possible lipid levels may be beneficial, even in patients with initially low cholesterol.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Lipidology

Context:

  • Lipid-lowering therapy, primarily HMG-CoA reductase inhibition (statins), is a cornerstone of cardiovascular risk management.
  • Recent studies explore the efficacy of statins in diverse patient populations, including those with low baseline cholesterol and in secondary prevention settings.

Purpose:

  • To evaluate the effectiveness of aggressive lipid lowering with statins in primary and secondary cardiovascular disease prevention.
  • To compare aggressive lipid-lowering therapy with conventional treatment and percutaneous coronary intervention (PTCA) in specific patient groups.

Summary:

  • The AirForce/Texas Coronary Atherosclerosis Prevention Study demonstrated successful lipid lowering with lovastatin in primary prevention patients with initially low total cholesterol.

Related Experiment Videos

  • The AVERT study in secondary prevention showed a trend favoring aggressive lipid lowering over conventional therapy in PTCA-treated patients, though not reaching statistical significance.

    • Impact:

    • Findings support the concept of achieving the lowest possible lipid levels for long-term cardiovascular benefit.
    • Aggressive lipid lowering may become a preferred initial strategy over invasive procedures in managing cardiovascular disease and type II diabetes mellitus.